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1. INTRODUCTION
HPLC introduction
The modern form of column chromatography has been called high performance, high
pressure, and high-resolution and high-speed liquid chromatography.
High-Performance  Liquid  Chromatography  (HPLC)  is  a  special  branch  of  column
chromatography in which the mobile phase is forced through the column at high speed.  As a
result  the  analysis  time is  reduced  by 1-2  orders  of  magnitude  relative  to  classical  column
chromatography and the use of  much smaller particles  of  the adsorbent  or  support  becomes
possible increasing the column efficiency substantially.1
Normal Phase Chromatography
In normal phase chromatography, the stationary phase is a polar adsorbent and the mobile
phase is generally a mixture of non-aqueous solvents.
            The silica structure is saturated with silanol groups at the end. These OH groups are
statistically disturbed over the whole of the surface. The silanol groups represent the active sites
(very polar) in the stationary phase. This forms a weak type of bond with any molecule in the
vicinity when any of the following interactions are present.
♦ Dipole-induced dipole
♦ Dipole-dipole
♦ Hydrogen bonding
♦ -Complex bonding
These situations arise when the molecule has one or several atoms with lone pair electron
or a double bond. The absorption strengths and hence k’ values (elution series) increase in the
following order.  Saturated hydrocarbon < olefins  < aromatics  < organic  halogen compounds
<sulphides< ethers< esters < aldehydes and ketones < amines <sulphones< amides < carboxylic
acids.  The strength of  interactions  depends not only on the functional  groups in  the sample
molecule but also on steric factors. If a molecule has several functional groups, then the most
polar one determines the reaction properties.
Chemically modified silica,  such as the aminopropyl,  cyanopropyl  and diol  phases  is
useful alternatives to silica gel as stationary phase in normal phase chromatography.
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The aminopropyl and cyanopropyl phases provide opportunities for specific interactions
between  the  analyte  and  the  stationary  phases  and  thus  offer  additional  options  for  the
optimizations  of  separations.  Other  advantages  of  bonded  phases  lie  in  their  increased
homogenity of the phase surface.
Resolution with  water  in  weak mobile  phase may be most  conveniently achieved by
drying  the  solvents  and  then  adding  a  constant  concentration  of  water  or  some  very  polar
modifier such as acetic acid or tri ethylamine (TEA) to the mobile phase. The addition of such
polar modifiers serves to deactivate the more polar shape as well as the reproducibility of the
retention times.
Reversed Phase Chromatography
In  1960’s  chromatographers  started  modifying  the  polar  nature  of  silanol  group  by
chemically reacting silica with organic silanes. The objective was to make less polar or non-polar
so that polar solvents can be used to separate water-soluble polar compounds. Since the ionic
nature of the chemically modified silica is now reversed i.e. it is non-polar or the nature of the
phase is reversed. The chromatographic separation carried out with such silica is referred to as
reversed- phase chromatography.
A large number of  chemically bonded stationary phases  based on silica are available
commercially. Table 1 lists some of the functional groups bonded in chemically modified silica.
Silica based stationary phases are still most popular in reversed phase chromatography however
other  absorbants  based  on  polymer  (styrene-divinyl  benzene  copolymer)  are  slowly  gaining
ground.
Simple compounds  are  better  retained  by the  reversed  phase  surface,  the  less  water-
soluble  (i.e.  the  more  non-polar)  they  are.  The  retention  decreases  in  the  following  order:
aliphatics> induced  dipoles  (i.e.  CCl4)  > permanent  dipoles  (e.g.CHCl3)  >  weak  lewis  bases
(ethers, aldehydes, ketones) > strong lewis bases (amines) > weak lewis acids (alcohols, phenols)
> strong lewis acids (carboxylic acids). Also the retention increases as the number of carbon
atoms increases.
As a general rule the retention increases with increasing contact area between sample molecule
and stationary phase i.e. with increasing number of water molecules, which are released during
the adsorption of a compound. Branched chain compounds are eluted more rapidly than their
corresponding normal isomers.
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In reversed phase systems the strong attractive forces between water molecules arising
from the 3-dimensional inter molecular hydrogen bonded network, from a structure of water that
must be distorted or disrupted when a solute is dissolved. Only higher polar or ionic solutes can
interact with the water structure. Non- polar solutes are squeezed out of the mobile phase and are
relatively insoluble in it but with the hydrocarbon moieties of the stationary phase.
Chemically bonded octadecylsilane (ODS) an alkaline with 18 carbon atoms it  is the
most  popular  stationary  phase  used  in  pharmaceutical  industry.  Since  most  pharmaceutical
compounds  are  polar  and  water  soluble,  the  majority  of  HPLC  methods  used  for  quality
assurance, decomposition studies, quantitative analysis of both bulk drugs and their formulations
use ODS HPLC columns. The solvent strength in reversed phase chromatography is reversed
from that of adsorption chromatography (silica gel) as stated earlier. Water interacts strongly with
silanol groups, so that, adsorption of sample molecules become highly restricted and they are
rapidly eluted as a result. Exactly opposite applies in reversed phase system; water cannot wet
the non-polar  (hydrophobic)  alkyl  groups such as  C18  of ODS phase  and therefore does  not
interact with the bonded moiety. Hence water is the weakest solvent of all and gives slowest
elution rate. The elution time (retention time) in reversed phase chromatography increases with
increasing amount of water in the mobile phase.
The essential equipment consists of an eluent, reservoir, a high-pressure pump, and an
injector for introducing the sample,  a column containing the stationary phase, a detector and
recorder. The development of highly efficient micro particulate bonded phases has increased the
versatility of the technique and has greatly improved the analysis of multi component mixtures.
The systems used are often described as belonging to one of four mechanistic types,
adsorption, partition, ion exchange and size-exclusion. Adsorption chromatography arises from
interaction between solutes on the surface of the solid stationary phase. Partition chromatography
involves a liquid stationary phase, which is immiscible with the eluent and coated on an inert
support. Adsorption and partition systems can be normal phase (stationary phase more polar than
eluent) or reversed phase (stationary phase less polar than eluent). Ion-exchange chromatography
involves a solid stationary phase with anionic or cationic groups on the surface to which solute
molecules  of  opposite  charge  are  attracted.  Size-exclusion  chromatography  involves  a  solid
stationary phase with controlled pore size. Solutes are separated according to their molecular
size, the large molecules enable to enter the pores eluting first. 
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The various components of a HPLC system are herewith described.
The HPLC system is shown in Fig.1.0
Figure no.1.0.HPLC system
Instrumentation:
Solvent delivery system
The mobile phase is pumped under pressure from one or several reservoirs and flows
through the column at a constant rate with micro particulate packing, there is a high-pressure
drop across a chromatography column. Eluting power of the mobile phase is determined by its
overall polarity, the polarity of the stationary phase and the nature of the sample components. For
normal phase separations eluting power increases with increasing polarity of the solvent but for
reversed phase separations, eluting power decreases with increasing solvent polarity. Optimum
separating conditions can be achieved by making use of mixture of two solvents. Some other
properties of the solvents, which need to be considered for a successful separation, are boiling
point, viscosity, detector compatibility, flammability and toxicity.
The most important component of HPLC in solvent delivery system is the pump, because
its  performance  directly  effects  the  retention  time,  reproducibility  and  detector  sensitivity.
Among  the  several  solvent  delivery  systems  (direct  gas  pressure,  pneumatic  intensifier,
reciprocating etc.) reciprocating pump with twin or triple pistons is widely used, as this system
gives less baseline noise, good flow rate, reproducibility etc.
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Solvent degassing system
The constituents of the mobile phase should be degassed and filtered before use. Several
methods are employed to remove the dissolved gases in the mobile phase. They include heating
and stirring, vacuum degassing with an aspirator, filtration through 0.45 filter, vacuum degassing
with an air-soluble membrane, helium purging ultra sonication or purging or combination of
these methods. HPLC systems are also provided an online degassing system, which continuously
removes the dissolved gases from the mobile phase.
Gradient elution devices
HPLC columns may be run isocratically, i.e., with constant eluent or they may be run in
the gradient elution mode in which the mobile phase composition varies during run. Gradient
elution is a means of overcoming the problem of dealing with a complex mixture of solutes. 
Sample introduction systems
Two means for analyte introduction on the column are injection in to a flowing stream
and a stop flow injection. These techniques can be used with a syringe or an injection valve.
Automatic  injector  is  a  microprocessor-controlled  version  of  the  manual  universal  injector.
Usually, up to 100 samples can be loaded in to the auto injector tray. The system parameters such
as flow rates, gradient, run time, volume to be injected, etc. are chosen, stored in memory and
sequentially executed on consecutive injections. 
Liquid chromatographic detectors
The function of the detector in HPLC is to monitor the mobile phase as it emerges from
the column. Generally, there are two types of HPLC detectors, bulk property detectors and solute
property detectors. 
Bulk property detectors
These detectors are based on differential measurement of a property, which is common to
both  the  sample  and  the  mobile  phase.  Examples  of  such  detectors  are  refractive  index,
conductivity and dielectric constant detectors.
Solute property detectors
Solute  property detectors  respond to  a  physical  property  of  the  solute,  which  is  not
exhibited by the pure mobile phase. These detectors measure a property, which is specific to the
sample, either with or without the removal of the mobile phase prior to the detection. Solute
property detectors which do not require the removal of the mobile phase before detection include
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spectrophotometric  (UV or  UV-Vis)  detector,  fluorescence  detectors,  polarographic,  electro-
chemical  and  radio activity  detectors,  whilst  the  moving  wire  flame ionization  detector  and
electron capture detector both require removal of the mobile phase before detection.
UV-Vis and fluorescent detectors are suitable for gradient elution, because many solvents
used in HPLC do not absorb to any significant extent.
Column and Column-packing materials
The heart of the system is the column.  In order to achieve high efficiency of separation,
the column material (micro-particles, 5-10 µm size) packed in such a way that highest numbers
of theoretical plates are possible.  
Silica (SiO2,  H2O) is  the most widely used substance for the manufacture of packing
materials. It  consists of a network of siloxane linkages (Si-O-Si) in a rigid three dimensional
structure  containing  inter  connecting  pores.  Thus  a  wide  range  of  commercial  products  is
available with surface areas ranging from 100 to800 m2/g. And particle sizes from 3 to 50 pim.  
The silanol groups on the surface of silica give it a polar character, which is exploited in
adsorption chromatography using non-polar organic eluents. Silica can be drastically altered by
reaction with organochlorosilanes  or  organoalkoxysilanes giving Si-O-Si-R linkages with the
surface. The attachment of hydrocarbon change to silica produces a non-polar surface suitable
for reversed phase chromatography where mixtures of water and organic solvents are used as
eluents. The most popular material is octadecyl-silica (ODS-Silica), which contains C18 chains,
but  materials  with  C2,  C6,  C8 and  C22 chains  are  also  available.  During  manufacture,  such
materials  may be reacted with a small  mono functional  silane (e.g.  trimethylchlorosilane)  to
reduce further the number of silanol groups remaining on the surface (end-capping). There is a
vast range of materials which have intermediate surface polarities arising from the bonding to
silica  of  other  organic  compounds  which  contain  groups  such  as  phenyl,  nitro,  amino  and
hydroxyl. Strong ion exchangers are also available in which sulphonic acid groups or quaternary
ammonium groups are bonded to silica. The useful pH range for columns is 2 to 8, since siloxane
linkages are cleaved below pH-2 while at pH values above eight silica may dissolve.
In HPLC, generally two types of columns are used, normal phase columns and reversed
phase columns. Using normal phase chromatography, particularly of non-polar and moderately
polar  drugs  can  make  excellent  separation.  It  was  originally  believed  that  separation  of
compounds in mixture takes place slowly by differential adsorption on a stationary silica phase.
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However, it now seems that partition plays an important role, with the compounds interacting
with the polar silanol groups on the silica or with bound water molecules. 
While normal phase seems the passage of a relatively non-polar mobile phase over a
polar stationary phase, reversed phase chromatography is carried out using a polar mobile phase
such as methanol, Acetonitrile, water, buffers etc., over a non-polar stationary phase. Ranges of
stationary phases (C18, C8, -NH2, -CN, -phenyl etc.) are available and very selective separations
can be achieved. The pH of the mobile phase can be adjusted to suppress the ionization of the
drug  and  thereby  increase  the  retention  on  the  column.  For  highly  ionized  drugs  ion-pair
chromatography is used.
Derivatization
In  HPLC derivatization is  used to enhance the sensitivity and selectivity of detection
when available detectors are not satisfactory for the underivatized compounds. Both ultra violet
absorbing  and  fluorescence  derivatives  have  been  widely  used.  Ultra  violet  derivatization
reagents include N-succinimidyl p-nitro phenyl acetate, phenyl hydrazine and 3, 5-dinitro benzyl
chlorides, while fluorescent derivatives can be formed with reagents such as dansyl chloride, 4-
bromo methyl-7-methoxy-coumarin and fluorescamine. Derivative formation can be carried out
before the sample is injected on to the column or by online chemical  reactions between the
column out let and the detector.
Gradient elution
Gradient  elution  or  solvent  programming  is  the  change  of  solvent  composition  during  a
separation  in  which  the  solvent  strength  increases  from  the  beginning  to  the  end  of  the
separation.  It  is  well  suited  to  the  analysis  of  samples  of  unknown  complexity  since  good
resolution is automatically provided for a wide range of sample polarities. There are two types of
gradient systems: Low-pressure gradient mixtures and high- pressure gradient mixtures. In the
former the solvents are mixed at atmosphere pressure and then pumped to the column, where as
in the later, solvents are pumped in to a mixing chamber at high pressure before going in to the
column.
Performance calculations
Calculating the following values (which can be including in a custom report) used to 
access overall system performance.
Relative retention
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Theoretical plates
Capacity factor
Resolution
Peak asymmetry
Plates per meter
The parameters used to calculate these system performance values for the separation of
two chromatographic components.  (Note:  Where the terms W and t both appear in the same
equation they must be expressed in the same units).
Relative retention (Selectivity):
µ = (t2 - ta) / (t1 - ta)
Theoretical plates:
n = 16 (t / W) 2
Capacity factor:
K' = (t2 / ta) - 1
Resolution:
R = 2 (t2 - t1) / (W2 + W1)
Peak asymmetry:
T = W0.05 / 2f
Plates per meter:
N = n / L
HETP:    L/n
Where, α = Relative retention.
t2 = Retention time of the second peak measured from point of injection.
t1 = Retention time of the first peak measured from point of injection.
ta = Retention time of an inert peak not retained by the column, measured from point of 
injection.
n = Theoretical plates.
t = Retention time of the component.
            W = Width of the base of the component peak using tangent method.
             K' = Capacity factor.
             R = Resolution between a peak of interest (p2) and the peak preceding it (p1)
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             W2 = Width of the base of component peak 2.
             W1 = Width of the base of component peak 1.
T= Peak asymmetry, or tailing factor.
              W0.05 = Distance from the leading edge to the tailing edge of the peak,            
Measured at a point 5 % of the peak height from the baseline.
              f = Distance from the peak maximum to the leading edge of the peak.
              N = Plates per meter.
              L = Column length, in meters.2,3,4
METHOD OPTIMIZATION
During the optimization stage, the initial sets of conditions that have evolved from the
first stages of development are improved or maximized in terms of resolution and peak shape,
plate counts asymmetry, capacity, elution time, detection limits, limit of Quantitation, and overall
ability to quantify the specific analyte of interest.
Optimization of a method can follow either of two general approaches: 
1. Manual 
2. Computer driven 
The manual approach involves varying one experimental variable at a time, while holding
all others constant, and recording changes in response .The variables might include flow rates,
mobile  or  stationary  phase  composition,  temperature,  detection  wavelength,  and  pH  this
univariate approach to system optimization is slow, time consuming and potentially expensive.
However, it may provide a much better understanding of the principles and theory involved and
of interactions of the variables. 
In the second approach, computer driven automated methods development, efficiency is
optimized while experimental input is minimized. Computer driven automated approaches can be
applied to many applications .In addition, they are capable of significantly reducing the time,
energy and cost of virtually all-instrumental methods development. 
The various parameters that include to be optimized during method development 
1. Mode of separation 
2. Selection of stationary phase 
3. Selection of mobile phase
4. Selection of detector 
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Selection of mode of separation 
In reverse phase mode, the mobile phase is comparatively more polar than the stationary
phase. For the separation of polar or moderately polar compounds, the most preferred mode is
reverse phase. The nature of the analyte is the primary factor in the selection of the mode of
separation. A second factor is the nature of the matrix.
Selection of stationary phase / column 
Selection of the column is the first and the most important step in method development the
appropriate choice of separation column includes three different approaches 
1. Selection of separation system 
2. The particle size and the nature of the column packing
3. The physical parameters of the column i.e. the length and the diameter 
Some of the important parameters considered while selecting chromatographic columns are
♦ Length and diameter of the column.
♦ Packing material.
♦ Shape of the particles.
♦ Size of the particles.
♦ % of Carbon loading
♦ Pore volume.
♦ Surface area.
♦ End capping.
The column is selected depending on the nature of the solute and the information about
the analyte. Reversed phase mode of chromatography facilitates a wide range of columns like
dimethyl silane (C2),  butylsilane (C4), octylsilane (C8), octadecylsilane (C18), base deactivated
silane (C18) BDS phenyl, cyanopropyl (CN), nitro, amino etc. C18    was chosen for this study
since it is most retentive one. The sample manipulation becomes easier with this type of column 
 Generally longer columns provide better separation due to higher theoretical plate numbers. As
the particle size decreases the surface area available for coating increases. Columns with 5-µm
particle size give the best compromise of efficiency, reproducibility and reliability. In this case,
the column selected had a particle size of 5 µm and a internal diameter of 4.6 mm
Peak shape is  equally important  in  method development.  Columns that  provide  symmetrical
peaks are always preferred while peaks with poor asymmetry can result in,
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♦ In accurate plate number and resolution measurement
♦ Imprecise quantitation 
♦ Degraded and undetected minor bands in the peak tail
♦ Poor retention reproducibility
A useful and practical measurement of peak shape is peak asymmetry factor and peak tailing
factor. Peak asymmetry is measured at 10% of full peak height and peak tailing factor at 5%.
Reproducibility of retention times and capacity factor is important for developing a rugged and
repeatable method
A column which gives separation of all the impurities and degradants from each other and
from Analyte peak and which is rugged for variation in mobile phase shall be selected.
 Selection of mobile phase 
The  primary  objective  in  selection  and  optimization  of  mobile  phase  is  to  achieve
optimum separation of all the individual impurities and degradants from each other and from
analyte peak
            In liquid chromatography, the solute retention is governed by the solute distribution
factor, which reflects the different interactions of the solute – stationary phase, solute – mobile
phase and the mobile phase – stationary phase. For a given stationary phase, the retention of the
given solute depends directly upon the mobile phase, the nature and the composition of which
has  to  be judiciously selected in  order  to  get  appropriate  and  required  solute retention.  The
mobile has to be adapted in terms of elution strength (solute retention) and solvent selectivity
(solute separation) Solvent polarity is the key word in chromatographic separations since a polar
mobile phase will give rise to low solute retention in normal phase and high solute retention in
reverse phase LC. The selectivity will be particularly altered if the buffer pH is close to the PKa
of the analytes the solvent strength is a measure of its ability to pull analyte from the column. It
is generally controlled by the concentration of the solvent with the highest strength.
The following are the parameters, which shall be taken into consideration while selecting
and optimizing the mobile phase.
♦ Buffer,
♦ pH of the buffer 
♦ Mobile phase composition.
Department of pharmaceutical analysis Page 11
Chapter 1                                                                                                                                      Introduction
Buffer, if any and its length:
Buffer  and  its  strength  play  an  important  role  in  deciding  the  peak  symmetries  and
separations. Some of the most, commonly employed buffers are 
♦ Phosphate  buffers  prepared  using  salts  like  KH2PO4,
K2HPO4,NaH2PO4,Na2HPO4,etc
♦ Phosphoric acid buffers prepared using H3PO4.
♦ Acetate buffers – Ammonium acetate, Sodium acetate, etc.
♦ Acetic acid buffers prepared using CH3COOH.
 The retention times also depend on the molar strengths of the buffer – Molar strength is
increasingly proportional  to  retention  times.  The  strength  of  the  buffer  can  be  increased,  if
necessary, to achieve the required separations.
               The solvent strength is a measure of its ability to pull analytes from the column. It is
generally controlled by the concentration of the solvent with the highest strength.
pH of the buffer:
pH plays an important role in achieving the chromatographic separations as it controls the
elution properties by controlling the ionization characteristics. Experiments were conducted 
using buffers having different pH to obtain the required separations.
It is important to maintain the pH of the mobile phase in the range of 2.0 to 8.0 as most
columns does not withstand to the pH which are outside this range. This is due to the fact that the
siloxane linkage area cleaved below pH 2.0, while pH valued above 8.0 silica may dissolve.
Mobile phase composition:
Most  chromatographic separations  can be achieved  by choosing the optimum mobile
phase composition. This is due to that fact that fairly large amount of selectivity can be achieved
by choosing the qualitative and quantitative composition of aqueous and organic portions. Most
widely  used  solvents  in  reverse  phase  chromatography  are  Methanol  and  Acetonitrile.
Experiments were conducted with mobile phases having buffers with different pH and different
organic phases to check for the best separations between the impurities. A mobile phase which
gives separation of all the impurities and degradants from each other and from analyte peak and
which is rugged for variation of both aqueous and organic phase by at least ±0.2% of the selected
mobile phase composition.
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Selection of detector: 
The detector was chosen depending upon some characteristic property of the analyte like UV
absorbance,  fluorescence,  conductance,  oxidation, reduction etc.  characteristics that  are to be
fulfilled by a detector to be used in HPLC determination are,
♦ High sensitivity, facilitating trace analysis
♦ Negligible baseline noise. To facilitate lower detection
♦ Large linear dynamic range 
♦ Low dead volume
♦ Non destructive to sample 
♦ Inexpensive to purchase and operate 
              Pharmaceutical ingredients do not all absorb UV light equally, so that selection of
detection wavelength is important. An understanding of the UV light absorptive properties of the
organic impurities and the active pharmaceutical ingredient is very helpful.
 For the greatest  sensitivity  λ  max should be used. UV wavelengths below 200 nm should be
avoided  because  detector  noise  increases  in  this  region.  Higher  wavelengths  give  greater
selectivity.5,21
METHOD VALIDATION
Method validation can be defined as (ICH)  “Establishing documented evidence, which
provides a high degree of assurance that a specific activity will consistently produce a desired
result or product meeting its predetermined specifications and quality characteristics”.
 Method  validation  is  an  integral  part  of  the  method  development,  it  is  the  process  of
demonstrating that analytical procedures are suitable for their intended use and that they support
the  identity,  quality,  purity,  and  potency of  the  drug  substances  and  drug  products.  Simply,
method  validation  is  the  process  of  proving  that  an  analytical  method  is  acceptable  for  its
intended purpose.
             Method Validation, however, is generally a one-time process performed after the method
has been developed to demonstrate that the method is scientifically sound and that it serves the
intended analytical purpose.
All  the variables  of  the  method should be considered,  including sampling procedure,
sample  preparation,  chromatographic  separation,  and  detection  and  data  evaluation.  For
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Absolute recovery = 
response of an analyte spike into matrix (processed)
response of analyte of pure standard (unprocessed)
X 100
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chromatographic methods used in analytical applications there is more consistency in validation
practice with key analytical parameters including 
(a) Recovery (b) Response function (c) Sensitivity (d) Precision (e) Accuracy
(f) Limit of detection (g) Limit of quantitation (h) Ruggedness (i) Robustness (j) stability (k)
system suitability.
(a) Recovery
The absolute recovery of analytical method is measured as the response of a processed spiked
matrix standard expressed as a percentage of the response of pure standard, which has not been
subjected to sample pre-treatment and indicates whether the method provides a response for the
entire amount of analyte that is present in the sample. It  is best established by comparing the
responses of extracted samples at low, medium and high concentrations in replicates of at least 6
with those non-extracted standards, which represent 100 % recovery.
Error: Reference source not found
If  an  internal  standard  is  used,  its  recovery  should  be  determined  independently  at  the
concentration levels used in the method.
(b) Response of function
In chromatographic methods of analysis, peak area or peak height may be used as response
function to define the linear relationship with concentration known as the calibration model. It is
essential  to  verify  the  calibration  model  selected  to  ensure  that  it  adequately  describes  the
relationship between response function (Y) and concentration (X).
(c) Sensitivity
The method is said to be sensitive if small changes in concentration cause large changes
in response function. The sensitivity of an analytical method is determined from the slope of the
calibration line. The limits of quantification (LOQ) or working dynamic range of bio analytical
method  are  defined  as  the  highest  and  lowest  concentrations,  which  can  determined  with
acceptable accuracy. It is suggested that, this be set at α 15% for both the upper and lower limit
of quantitation respectively.  Any sample concentration that falls outside the calibration range
cannot  be interpolated from the calibration line and extrapolation of  the calibration curve  is
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discouraged. If the concentration is over range, the sample should be diluted in drug-free matrix
and re-assayed. 
(d) Precision 
The purpose of carrying out a determination is to obtain a valid estimate of a ‘true’ value.
When one considers the criteria according to which an analytical procedure is selected, precision
and  accuracy  are  usually  the  first  time  to  come  to  mind.  Precision  and  accuracy  together
determine the error of an individual determination. They are among the most important criteria
for judging analytical procedures by their results. 
               Precision refers to the reproducibility of measurement within a set, that is, to the scatter
of dispersion of a set about its central value. The term ‘set’ is defined as referring to a number (n)
of independent replicate measurements of some property. One of the most common statistical
terms employed is the standard deviation of a population of observation. Standard deviation is
the square root of the sum of squares of deviations of individual results for the mean, divided by
one less than the number of results in the set. The standard deviation S, is given by
S = 
( )∑
−
−
−
n
1i
2
i xx1n
1
Standard deviation has the same units as the property being measured.
           The square of standard deviation is called variance (S2). Relative standard deviation is the
standard deviation expressed as a fraction of the mean, i.e., S/x. It is some times multiplied by
100 and expressed as a percent relative standard deviation. It becomes a more reliable expression
of precision. 
                % Relative standard deviation = S/x X100.
(e) Accuracy 
Accuracy normally refers to the difference between the mean x, of the set of results and
the true or correct value for the quantity measured. According to IUPAC accuracy relates to the
difference between results (or mean) and the true value. For analytical methods, there are two
possible ways of determining the accuracy, absolute method and comparative method.
Accuracy is best reported as percentage bias, which is calculated from the expression
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               Since for real samples the true value is not known, an approximation is obtained based
on spiking drug – free matrix to a nominal concentration. The accuracy of analytical method is
then determined at each concentration by assessing the agreement between the measured and
nominal concentrations of the analytes in the spiked drug – free matrix sampler.
 Calibration
Calibration is the most important step in bioactive compound analysis. A good precision
and  accuracy  can  only  be  obtained  when  a  good  calibration  procedure  is  adopted.  In  the
spectrophotometric methods, the concentration of a sample cannot be measured directly, but is
determined  using  another  physical  measuring  quantity  ‘y’  (absorbance  of  a  solution).  An
unambiguous empirical or theoretical relationship can be shown between this quantity and the
concentration of an analyte. The calibration between y = g (x) is directly useful and yields by
inversion of the analytical calculation function.
               The calibration function can be obtained by fitting an adequate mathematical model
through the experimental data. The most convenient calibration function is linear, goes through
the origin and is applicable over a wide dynamic range. In practice, however, many deviations
from the ideal calibration line may occur. For the majority of analytical techniques the analyst
uses the calibration equation.
                         Y = a + bx.
                     In calibration, univariate regression is applied, which means that all observations
are dependent upon a single variable X.
 Standard deviation of slope (Sb)
The standard deviation of slope is proportional to standard error of estimate and inversely
proportional to the range and square root of the number of data points.
Sb = )2n(
)yˆy(n
1i
2
ii
−
−∑
= ∑
=
−
n
1i
2
i
_
i )xx(
1
Where Xi is the arithmetic mean of Xi values.
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Standard deviation of intercept, (Sa)
Intercept values of least squares fits of data are often to evaluate additive errors between
or among different methods.
Sa = )2n(
yˆy
n
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Where Xi denote the arithmetic mean of xi, values.
Correlation Coefficient, (r) 
The correlation coefficient r (x,y) is more useful to express the relationship of the chosen
scales. To obtain a correlation coefficient the covariance is divided by the product of the standard
deviation of x and y.
 r =     
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Linearity and sensitivity of the method      
Knowledge  of  the  sensitivity  of  the  color  is  important  and  the  following  terms  are
commonly employed for expressing sensitivity.  According to Lambert – Beer’s law, log intensity
of incident radiations
==
lightdtransmitteofIntensity
lightincidentofIntensityLogA
±ct
The absorbance (A) is proportional to the concentration (c) of the absorbing species, if
absorptivity (∈) and thickness of the medium (t) are constant. When c is in moles per liter, the
constant is called molar absorptivity. Beer’s law limits and ∈max values are expressed as µg ml-1
and mole-1 cm-1respectively.Sandell’s sensitivity refers to the number of µg of the drug to be
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determining, converted to the colored product, which in a column solution of cross section 1cm2
shows an absorbance of 0.001 (expressed as µg cm-2).
(f) Limit of detection (LOD)
The  limit  of  detection  (LOD)  of  an  analytical  method  may  be  defined  as  the
concentration, which gives rise to an instrument signal that is significantly different from the
blank. For spectroscopic techniques or other methods that reliably upon a calibration curve for
quantitative measurements, the IUPAC approach employs the standard deviation of the intercept
(Sa), which may be related to LOD and the slope of the calibration curve, b, by
LOD = 3 Sa / b
(g) Limit of quantitation (LOQ)
The LOQ is the concentration that can be quantitate reliably with a specified level of
accuracy and precision.  The LOQ represent  the  concentration  of  analyte  that  would yield  a
signal-to-noise ratio of 10.
                   LOQ = 10 Sa / b
Where, Sa- the estimate is the standard deviation of the peak area ratio of analyte to IS (5
injections) of the drugs. b -is slope of the corresponding calibration curve.
(h) Ruggedness
Method  Ruggedness  is  defined  as  the  reproducibility  of  results  when  the  method  is
performed under actual use conditions. This includes different analysts, laboratories, columns,
instruments, source of reagents, chemicals, solvents etc. Method ruggedness may not be known
when a method is first developed, but insight is obtained during subsequent use of that method.
(i) Robustness
The concept of robustness of an analytical procedure has been defined by the ICH as “a
measure  of  its  capacity  to  remain  unaffected  by  small  but  deliberate  variations  in  method
parameters”. The robustness of a method is the ability to remain unaffected by small changes in
parameters such as pH of the mobile phase, temperature, % organic solvent strength and buffer
concentration  etc.  to  determine  the  robustness  of  the  method  experimental  conditions  were
purposely altered and chromatographic characters were evaluated. 
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(j) Stability
To generate reproducible and reliable results, the samples, standards and reagents used
for the HPLC method must be stable for a reasonable time (e.g. one day, one week, and one
month depending upon need). For example, the analysis of even a single sample may require ten
or  more  chromatographic  runs  to  determine  the  system  suitability,  including  standard
concentrations to create a working analytical curve and duplicate or triplicate injections of the
sample to be assayed.
(k)System suitability
             System suitability experiments can be defined as tests to ensure that the method can
generate results of acceptable accuracy and precision. The requirements for system suitability are
usually developed after method development and validation have been completed. (or) The USP
(2000) defines parameters that can be used to determine system suitability prior to analysis.6,7,22
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2.REVIEW OF LITERATURE
 Lehr. G, Yuen. SM et al., developed a specific liquid. The system was found to be free from
any interferences from the 4 known related compounds of the 2 major components and is
useful as a screening procedure for 7-chloro-1,3-dihydro-5-phenyl-2H-1, 4-benzodiazepin-2-
one-4-oxide,the  principal  degradation  product  of  chlordiazepoxide  hydrochloride.
Chromatographic  method  was  developed  for  determination  of  clidinium  bromide  and
clidinium bromide-chlordiazepoxide hydrochloride combinations in capsules. The procedure
uses  a  Partisil  10  ODS-3  column  and  a  mobile  phase  consisting  of  acetonitrile-0.3M
ammonium phosphate (32 + 68)  (pH = 4.3).  The detection wavelength  is  235 nm. Four
commercial samples of the single ingredient were tested results compared favorably with the
compendial method. Two commercial samples of the combination product were tested by the
proposed method and results reported.8
 Savedra. M, Soto C et al.,  performed direct and simple first derivative spectrophotometric
method has been developed for the simultaneous determination of clidinium bromide and
chlordiazepoxide  in  pharmaceutical  formulations.  Acetonitrile  was  used  as  solvent  for
extracting the drugs  from the formulations  and subsequently the samples  were evaluated
directly by derivative spectrophotometry. Simultaneous determination of the drugs can be
carried  out  using  the  zero-crossing  method  for  clidinium  bromide  at  220.8  nm and  the
graphical method for chlordiazepoxide at 283.6 nm. The calibration graphs were linear in the
ranges from 0.983 to 21.62 mg/ml of clidinium bromide and from0. 740 to 12.0 mg/l of
chlordiazepoxide.9
 NuhaKattan, SafwanAshour et al.,carried out a sensitive and precise RP-HPLC method has
been  developed  for  the  simultaneous  estimation  of  clidinium  bromide  (CDB)  and
chlordiazepoxide  (CDZ)  in  pure  and  pharmaceutical  formulations.  The  separation  was
achieved on a Nucleodur C8 (mm i.d., 5µm particle size) column at 25°C. CH3CN: MeOH:
NH4OAc0.1M  (30:40:30,  v/v/v)  was  used  as  the  mobile  phase  at  a  flow  rate  of
1.0mLmin−1 and  detector  wavelength  at  218nm.  Almotriptan  (ALT)  was  used  as  internal
standard.  The  method  showed  good  linearity  in  the  ranges  of  2.5–300.0  and  3.0–
500.0µgmL−1 for CDB and CDZ, respectively. The percentage recovery obtained for CDB
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and CDZ was 100.40–103.38 and 99.98–105.59%, respectively. LOD and LOQ were 0.088
and 0.294µgmL−1 for CDB and 0.121 and 0.403µgmL−1 for CDZ, respectively.10
 Pallavi R, AshutoshPathak et al.,has donea validation of a stability indicating reverse-phase
high-performance  liquid  chromatography  method  for  the  simultaneous  estimation  of
clidinium  bromide  and  chlordiazepoxidefrom  their  combination  drug  product.
Chromatographic separations are performed at ambient temperature on a Phenomenex Luna
C18 (250 mm × 4.6 mm, i.d., 5 µm) column using a mobile phase consistingof potassium
dihydrogen phosphate buffer (0.05 M, pH 4.0 adjusted with 0.5% orthophosphoric acid):
methanol:  acetonitrile  (40:40:20,  v/v/v).  The  flow rate  is  1.0  mL/min,  and the  detection
wavelength is 220 nm.11
 Sajel.kpatel,  N.  J.  Patel,  et  al.,  performed  a  binary  mixture  of  imipramine  HCl  and
chlordiazepoxide was determined by three different spectrophotometric methods. The first
method  involved  determination  of  imipramine  HCl  and  chlordiazepoxide  using  the
simultaneous  equations  and  the  second  method  involved  absorbance  ratio  method.
Imipramine has absorbance maxima at 251 nm, chlordiazepoxide has absorbance maxima at
264.5 nm and isoabsorptive point is at 220 nm in methanol. Linearity was obtained in the
concentration ranges of 1-25 and 1-10 µg/ml for Imipramine HCL and Chlordiazepoxide,
respectively.  The third method involved determination of these two drugs using the first-
derivative spectrophotometric technique at 219 and 231.5 nm over the concentration ranges
of 1-20 and 2-24 µg/ml with mean accuracies 99.46±0.78 and 101.43±1.20%, respectively.12
 Hoffmann-La,  Nutleyet  al.,developed  capillary  electrophoresis  (CE)  method  utilizing
indirect  ultraviolet  (UV)  detection  was  developed  for  the  determination  of  a  non-UV
absorbing  degradation  product,  Ro  5–5172,  in  clidinium  bromide  drug  substance.  The
electrophoresis  buffer  consisted  of  sodium  phosphate  and  benzyltrimethylammonium
bromide. Rinsing the capillary with sodium hydroxide followed by water then fresh capillary
electrophoresis buffer was found to significantly improve the reproducibility of the migration
times of the analytes. To further improve run-to-run reproducibility, an internal marker was
used to account for differences in injection volumes and migration times between runs. The
precision of the method was found to be less than 1% relative standard deviation for the
migration time ratio and peak area ratio of Ro 5–5172 to the internal standard. The method
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was  found  to  be  linear  for  0.05–1%  Ro  5–5172  with  respect  to  a  10  mg  ml−1 sample
preparation.  The limit  of detection was found to be less than 0.01% Ro 5–5172. Results
obtained for the analysis of a clidinium bromide drug substance lot using this CE method and
a thin layer chromatography method were compared and found to be in agreement.13
 Aravind.Doki, Kamarapu.SK et al.,the study describes method development and subsequent
validation of RP-HPLC method for simultaneous estimation of Clidinium bromide (CDB),
Chlordiazepoxide  (CDZ)  and  Dicyclomine  hydrochloride  (DICY)  in  bulk  and  combined
tablet dosage forms. Chromatographic separation was achieved on a Kromasil C18 (250 mm
× 4.6 mm id, 5µm) column using a mobile phase ratio consisting of (40:30:30) Methanol:
Acetonitrile: Potassium di hydrogen phosphate buffer (0.05M, PH 4.0 adjusting with 0.5%
Ortho phosphoric acid) at flow rate 1.0 ml/min. The detection wavelength is 270 nm. The
retention  times  of  Clidinium bromide,  Chlordiazepoxide  and  Dicyclomine  hydrochloride
were found to be 7.457 min, 4.400 min and 3.397 min respectively.14
 Butterfield  AG,  Matsui  FFet  al.,carried  out  a  rapid,  precise,  forward-phase  (adsorption)
high-performance liquid chromatographic  procedure is presented for the determination of
chlordiazepoxideand  two  common  impurities,  7-  chloro-1,3-dihydro-5  –  phenyl-2H-1,4-
benzodiazepine – 2 – one 4- oxidant 2amino  –  5-chlorobenzophenone,  in  commercial
formulations and for the determination of the benzophenone in the chlordiazepoxide drug
substance. The method involves simultaneous quantitation of chlordiazepoxide and the 1,3-
dihhydro impurity,  followed by quantitation of the benzophenone from a separate sample
extract  using a second mobile phase.  A single microparticulate  silica gel  column is  used
throughout. Nitrazepam and o-dinitrobenzene are the internal standards; Quantitation is by
peak area using a computing integrator,  except that  the peak due to the benzophenone is
quantitated by peak height. The described procedure is of equivalent precision, but superior
accuracy, to the BP 1973 spectrophotometric procedure for the analysis of chlordiazepoxide
in  chlordiazepoxide  formulations.  Quantitation  of  the  1,3-dihydro  and  the  benzophenone
impurities at levels as low as 6.3 and 0.9 mg, respectively, is demonstrated.15
 Roberts  SE,  Delaney  MFet  al.,  performed  a  quantitative  high-performance  liquid
chromatographic  method  using  an  octadecylsilane  column  and  a  methanol-water  mobile
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phase was employed for the determination of chlordiazepoxide, chlordiazepoxideand related
impurities in capsule and tablet preparations. Each component is well separated and directly
detected by 254 nm absorption. For chlordiazepoxide and chlordiazepoxidethe coefficient of
variation for replicated injections was below 1%. Recovery of authentic samples ranged from
98.4 to 101.6% for both capsule and tablet formulations.16
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3. AIM OF WORK
The literature survey revealed that few analytical methods are reported for the estimation
of  Clidinium bromide  and  Chlordiazepoxide  in  the  pharmaceutical  combined  tablets  dosage
forms.
Now adays HPTLC, HPLC are most valuable analytical techniques for pharmaceutical
they will  remain a useful  tool  in the future despite  further  advances in analytical  chemistry,
because of several  overwhelming advantages which include speed, specificity and sensitivity
availability of multiple methods for the estimation of drugs their formulation is advantageous
and  a  suitable  method  may  be  adopted  by  an  analyst  as  per  purpose  of  analysis  and
infrastructural facilities available. In the project it was planned to optimize the assay method for
estimation of Clidinium bromide and Chlordiazepoxide based on the literature survey made. So
the present work is  aimed at  development  of Isocratic Reverse Phase HPLC method for the
Clidinium bromide and Chlordiazepoxide in combined tablet dosage form and its validation as
per ICH guide lines.
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4. PLAN OF WORK
The plan of the proposed work includes the following steps.
Step 1 - To undertake solubility studies and analytical studies of Clidinium bromide and     
chlordiazepoxide and to develop initial HPLC chromatographic conditions.
Step  2   -   Development of suitable mobile phase.
Step  3   -   Selection of suitable detection wavelength.
Step 4    -  Setting up of initial HPLC chromatographic conditions for the assay of 
Clidiniumbromide and chlordiazepoxide.
Step  5   -  Optimization of initial chromatographic conditions.
Step 6    -  Analytical method validation of the developed RP-HPLC methods as per I.C.H 
guidelines.
Step  7  -  Evaluation of analytical method validation report generated for the developed method.
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5. DRUG PROFILE
Clidiniumbromide:-17, 18
Fig no: 2 Structure of clidinium bromide
Molecular formula : C22H26NO3
Molecular weight : 352.447 g.mol-1
Chemical name : 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-
                                                   Methyl-Azabicyclo[2.2.2]octan-1-ium bromide
Category : Anti cholinergic/Antiplasmodic
CAS number                 : 7020-55-5
Description : White crystalline
Solubility : Clidinium bromide is soluble in water and very       
Soluble in DMSO and methanol
PKavalue  : 11.6
Storage : Stored at 40C
Melting point  : 240-2410C
Therapeutic Uses          : Peptic ulcer disease,GI motility disturbances,
                                                 Acute enter colitis 
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Pharmacology:
Indication  For  the  treatment  of  peptic  ulcer  disease  and  also  to  help  relieve
abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis,
and irritable bowel syndrome.
Pharmacodynamics:
Clidinium  is  a  synthetic  anticholinergic  agent  which  has  been  shown  in
experimental and clinical studies to have a pronounced antispasmodic and antisecretory
effect on the gastrointestinal tract. 
Mechanism of Action:
Clidinium – AntiCholinergics inhibit the muscarinic actions of acetylcholine on
structures innervated by postganglionic cholinergic nerves as well as on smooth muscles
that  respond  to  acetylcholine  but  lack  cholinergic  innervation.  These  postganglionic
receptor sites are present in the autonomic effecter cells of the smooth muscle, cardiac
muscle,  sinoatrial  and atrioventricular  nodes,  and exocrine glands.  Depending on the
dose,  anticholinergics  may  reduce  the  motility  and  secretary  activity  of  the
gastrointestinalsystem. 
Inhibits  muscarinic  actions  of  acetylcholine  at  postganglionic  parasympathetic
neuroeffector sites primarily inhibiting the M1 muscarinic receptors
PHARMOCOKINETICS:
Absorption:
It is a good adsorbent.
Bioavailability:
Incompletely absorbed from the GI tract (apparently from the intestines) because 
completely ionized.
Onset of action:
Following oral administration, Anti-Secretary activity occurs within <1 hour.
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Duration:
Following oral administration, anti-secretary activity persists for ≤hours.
Distribution:
Does not readily penetrate the CNS or the eye.
Not known whether clidinium bromide crosses the placenta or is distributed into milk.
Metabolism:
Principally in the liver to its 3-hydroxyalcohol.
Elimination Route:
Limited data in 2 adults, approximately 36% of dose excreted in urine within 7
days of oral administration, with 90% of urinary excretion occurring within the first day;
20–46% eliminated in feces.
Half-life:
Biphasic; in 2 adults, initial half-life was 2.4 hours and terminal half-life was 20 hours
Contraindications:
• Glaucoma (to avoid mydriasis).
• Prostatic hypertrophy or benign bladder neck obstruction
Adverse Effects:
Xerostomia,Blurred vision,Constipation, Urinary hesitancy.
.
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DRUG PROFILE
Chlordiazepoxide :19,20
Fig  no:  3  Structure  of
chlordiazepoxide
Molecular  formula : C22H26CLNO3
Molecular weight : 299.75 g-mol-1
Chemical name : 7-chloro-2-methylamino-5-phenyl-3H-
          1,4-benzodiazepine-4-oxide
Category : Antianxiety, hypnotics and sedatives
CAS number : 58-25-3
PKa value : 4.8
Description : White, light yellow crystal or crystalline powder
Solubility : Chlordiazepoxide is  slightly soluble in  water  and
soluble
in Ethanol,glacial acetic acid
Storage : Stored at room temperature
Melting point : 236.20
Mechanism of Action:
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            Chlordiazepoxidebindstostereo  specific  benzodiazepine  binding  sites  on
GABA(A)  receptor  complexes  at  several  sites  within  the  central  nervous  system,
including the limbic system and reticular formation. This results in an increased binding
of the inhibitory neurotransmitter GABA to the GABA (A) receptor.  BZDs, therefore
enhance  GABA-mediated  chloride  influx  through  GABA receptor  channels,  causing
membrane  hyper  polarization.  The  neuro-inhibitory  effects  result  in  the  observed
sedative, hypnotic,anxiolytic,and muscle relaxant properties.
Pharmacokinetics:
Chlordiazepoxide  is  a  long  acting  benzodiazepine  drug.  The  half-life  of
Chlordiazepoxide  is  5  –  30  hours  but  has  an  active  benzodiazepine  metabolite
(desmethyldiazepam)  which  has  a  half-life  of  36  –  200  hours. The  half-life  of
chlordiazepoxide increases significantly in the elderly which may result  in prolonged
action as well as accumulation of the drug during repeated administration. Delayed body
clearance of the long half-life active metabolite also occurs in those over 60 years of age
which  further  prolongs  the  effects  of  the  drugs  with  additional  accumulation  after
repeated dosing.
Interactions:
Some of the major interactions involving Chlordiazepoxide are listed below.
• ACE inhibitors, Adrenergic neuroneblockers, Angiotensin II receptor 
antagonists, Betablockers, Calciumchannelblockers,
• Clonidine, Diazoxide,Diuretics,Hydralazine, Methyldopa, Minoxidil,  
• SodiumNitroprussideenhanced hypotensive effect
• Alcohol, barbiturates, opiates, antihistamines, antipsychotics - increased sedative 
effect in combination with Benzodiazapines.
• Cimetidine - metabolism of benzodiazepines inhibited by cimetidine (increased 
plasma concentration)
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• Disulfiram - metabolism of benzodiazepines inhibited by disulfiram (increased 
sedative effects)
Trade name : Librax
Strength : (Clidinium  bromide  2.5mg,Chlordiazepoxide
5.0mg)
Side effects : Confusion,Constipation,Drowsiness,Fainting,
Altered sex drive,Liver problems,Nausea,
Lack of muscle coordination,Yellow eyes and skin
Minor menstrual irregularities, Skin rash or eruptions
Swelling due to fluid retention
Contraindications:
Use of chlordiazepoxide should be avoided in individuals with the following conditions:
• Myasthenia gravis
• Acute intoxication with alcohol, narcotics, or other psychoactive substances
• Ataxia
• Severe hypoventilation
• Acute narrow-angle glaucoma
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6. EXPERIMENTAL WORK
6.1 MATERIALS AND METHODS:-
Table No.1
 List of Reagents and chemicals used:-
S. No Name of chemical Grade Manufactured By
1. Methanol HPLC Merck Specialty Pvt. Ltd
Mumbai
2. Ortho phosphoric acid Analytical Ranbaxy fine chemical Industry
Mumbai
3. Tri-ethylamine HPLC Merck Specialty Pvt. Ltd
Mumbai
4. Potassium di-hydrogen
phosphate
HPLC Merck Specialty Pvt. Ltd
Mumbai
5. Water HPLC MILLI-Q
Table.No.2
List of Instruments used:-
S. No Name of Instrument Manufactured by
1. Control dynamics pH meter Lab India
2. Balance Sartorius
3. LC-2010 CHT HPLC Waters
4. Sonicator Spectra lab
5. UV-Visible Spectroscopy
PERKINELMER
with LAMDA25
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TableNo.3
Active pharmaceutical Ingredient (pure drug)used:-
S.
No
Name % Purity Supplier Specification
1. Clidinium bromide 99.8% Lara labs Reference  Standard
2. Chlordiazepoxide 99.8% Lara labs Reference  Standard
TableNo.4 
Marketed Formulationused:-
S.No Brand Name Manufacturer
1. Librax (7.5mg) Torrent Pharmaceuticals
Solubility:
Solubility of drugs were observed by dissolving it in different solvents and it was found 
that drug having good solubility in water. Based on solubility we have selected the phosphate 
buffer for this work. Solubility of drug was observed by dissolving it in different solvents and it 
was found that drug having good solubility in followings.
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SOLVENT
SOLUBILITY
Clinidiumbromide and Chlordizepoxide
Water
Phosphate Buffer
+
+
Acetonitrile
Methanol
+
+
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6.2 METHOD DEVELOPMENT
Determination of ISOBESTIC point of Clidinium bromide and Chlordizepoxide by UV-Visible
spectrophotometry
Sample Preparation:-
Accurately Weighed and transferred Clidinium bromide and Chlordiazepoxide equivalent
to 25 mg and 25 mg into 50 mL clean dry volumetric flask, 50 mL of methanol was added,
sonicated for 5 minutes, and filtered through 0.45 µm nylon membrane filter. Pipette out both 5
mL of  each  solutions  transferred  into  50  mL volumetric  flask,  and  diluted  to  50  mL with
methanol in 50 mL volumetric flask,  and scanned between 200 to 400 by UV spectroscopy.
Shown in Figure 1
Initialization of the instrument
Initially, Column was placed on the instrument and the instrument was switched on and
washed with Methanol:Water (20:80 V/V) for 30min. Then the mobile phase ran into 30min to
obtain column saturation.
Selection of mobile phase:
The method development  and validation of  Clidinium bromide and Chlordiazepoxide
requires greater resolution. Hence different solvent systems were tried.
The trails are using LC-2010 CHT HPLC waters equipped with UV detector and isocratic
pump. The system controlled by WATERS EMPOWER2 software.
Selection of flow rate:
            The flow rate of Clidinium bromide and Chlordiazepoxide were tried from 1.0 mL to 1.5 mL
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TRIAL-1
Preparation of Buffer:
The buffer was prepared by dissolving 5.4 g of potassium di-hydrogen orthophosphate in
2000ml  of  water  and  adjusted  pH to  4.0  with  orthophosphoric  acid.  Filter  through  0.45µm
membrane filter.
Preparation of Mobile phase:
Degassed  mixture  of  Buffer:  Methanol  (60:40V/V)  in  the  ratio  of  respectively.Filter
through 0.45 µ membrane filter and degas.
Standard preparation:
The quantity containing 5mg of Clidinium bromide and 10mg of Chlordiazepoxide was
weighed and transferred in to a 25ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45µm membrane filter. From this
5ml was pipetted out in to a 25ml volumetric flask and made up to the volume with mobile
phase. The solution contains 40 µg/ mL and 80 µg/ mL concentration of Clidinium bromide and
Chlordiazepoxide respectively. The chromatogram was shown in Figure-2.
Chromatographic Condition:
Equipment : High performance liquid chromatography equipped with 
                                      Auto Sampler and UV detector
 Column                      :           OC C8 (250 x 4.5mm, 5.0µm) or equivalent
Mode of operation      :            Isocratic
Flow rate                     :           1.0ml/min
Wave length                :           240nm
Injection volume         :           10µl
Column oven               :           Ambient
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Run time                      :          30min
Temperature                :           250C
TRIAL-2
Preparation of Buffer:
The buffer was prepared by dissolving 5.4g of potassium di-hydrogen orthophosphate in
2000  ml  of  water  and  adjusted  pH  to  4.0  with  orthophosphoric  acid.  Filter  through
0.45 µm membrane filter.
Preparation of Mobile phase:
Degassed mixture of Buffer: Methanol (V/V) in the ratio of 70:30%respectively Filter
through 0.45 µ membrane filter and degas.
Standard preparation:
The quantity containing 5 mg of Clidinium bromide and 10 mg of Chlordiazepoxide was
weighed and transferred in to a 25 ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this 5
ml was pipetted out in to a 25 ml volumetric flask and made up to the volume with mobile phase.
The  solution  contains  40  µg/  mL and  80  µg/  mL concentration  of  Clidinium bromide  and
Chlordiazepoxide respectively. The chromatogram was shown in Figure 3.
Chromatographic Condition:
Equipment          : High performance liquid chromatography equipped with 
                                     Auto Sampler and UV detector
Column                       :           OC C8 (250 x 4.5mm, 5.0µm) or equivalent
Mode of operation      :            Isocratic
Flow rate                    :            1.2ml/min
Wave length               :            240nm
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Injection volume        :            10µl
Column oven              :           Ambient
Run time                     :           30min
Temperature               :           250C
TRIAL-3
Preparation of Buffer:
The buffer was prepared by dissolving 5.4g of potassium di-hydrogen orthophosphate in
2000ml of water. To 2000ml of phosphate buffer and adjust pH to 4.0 with phosphoric acid.
Filter through 0.45µmmembrane filter.
Preparation of Mobile phase:
Degassed mixture of Buffer: Methanol (V/V) in the ratio of 70:30% respectively Filter
through 0.45 µ membrane filter and degassed.
Standard preparation:
The quantity containing 5 mg of Clidinium bromide and 10 mg of Chlordiazepoxide was
weighed and transferred in to a 25 ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this 5
ml was pipetted out in to a 25 ml volumetric flask and made up to the volume with mobile phase.
The  solution  contains  40  µg/  mL and  80  µg/  mL concentration  of  Clidinium bromide  and
Chlordiazepoxide respectively. The chromatogram was shown in Figure 4.
Chromatographic Condition:
Equipment : High performance liquid chromatography equipped with 
                                         Auto Sampler and PDA detector
 Column                      :           OC C8 (250 x 4.5mm, 5.0µm) or equivalent
Flow rate                     :           1.5ml/min
Mode of operation      :            Isocratic
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Wave length             :              240nm
Injection volume      :              10µl
Column oven           :               Ambient
Run time                  :              30min
Temperature            :               250C
TRIAL-4
Preparation of Buffer:
            The buffer was prepared by dissolving 5.4g of potassium dihydrogen orthophosphate in
2000ml of water. To 2000ml of phosphate buffer and adjust pH to 4.0 with phosphoric acid.
Filter through 0.45µ membrane filter.
Preparation of Mobile phase:
            Filtered and degassed mixture of Buffer (pH 4.0): Methanol (80:20) v/v in the ratio of
80:20. And filter through 0.45µ membrane filter. 
Standard preparation:
The quantity containing 5 mg of Clidinium bromide and 10 mg of Chlordiazepoxide was
weighed and transferred in to a 25 ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this 5
ml was pipetted out in to a 25 ml volumetric flask and made up to the volume with mobile phase.
The  solution  contains  40  µg/  mL and  80  µg/  mL concentration  of  Clidinium bromide  and
Chlordiazepoxide respectively. The chromatogram was shown in Figure 5.
Chromatographic Condition:
Equipment          : High performance liquid chromatography equipped with 
                                       Auto Sampler and UV detector
Column                       :           OC C8 (250 x 4.5mm, 5.0µm) or equivalent
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Flow rate                       :            1.5ml / min
Mode of operation        :             Isocratic
Wave length                  :            240nm
Injection volume           :             10µl
Column oven                 :            Ambient
 Run time                       :            30min
Temperature                  :             250C
OPTIMIZED METHOD
Preparation of Buffer:
The buffer was prepared by dissolving 5.4 g of potassium di-hydrogen orthophosphate in
2000ml  of  water  and  adjust  pH to  4.5  with  phosphoric  acid.  Filter  through  a  0.45µ  nylon
membrane filter.
Preparation of Mobile phase:
Filtered and degassed mixture of  Buffer (pH 4.5): Methanol (80:20) v/v in the ratio of
80:20. And filter through 0.45µ membrane filter. 
Standard Preparation:
The quantity containing 5 mg of Clidinium bromide and 10 mg of Chlordiazepoxide was
weighed and transferred in to a 25 ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this 5
ml was pipetted out in to a 25 ml volumetric flask and made up to the volume with mobile phase.
The  solution  contains  40  µg/  mL and  80  µg/  mL concentration  of  Clidinium bromide  and
Chlordiazepoxide respectively. The chromatogram was shown in Figure 6.
Chromatographic Conditions:
Equipment          : High performance liquid chromatography equipped with 
                           Auto Sampler and PDA detector
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 Column                       :           OC C8 (250 x 4.5mm, 5.0µm) or equivalent
Flow rate                      :           1.5ml/min
Mode of operation       :            Isocratic
Wave length                 :           240nm
Injection volume          :           10µl
Column oven                :           Ambient
Run time                       :          30min
Temperature                 :           250C
6.2.1 ASSAY OF CLIDINIUM BROMIDE AND CHLORDIAZEPOXIDE:
Standard Preparation:
The  quantity  containing  5  mg  of  Clidinium  bromide  and  10  mg  of  Chlordiazepoxide  was
weighed and transferred in to a 25 ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this 5
ml was pipetted out in to a 25 ml volumetric flask and made up to the volume with mobile phase.
The  solution  contains  40  µg/  mL and  80  µg/  mL concentration  of  Clidinium bromide  and
Chlordiazepoxide respectively.The results was tabulated in  Table 6 & The chromatogram was
shown in Figure 7.
Sample preparation:
Weigh and powder 20 tablets and weigh powder equivalent to135mg of  the sample was
taken and transferred in to a 25ml volumetric flask and made up to the volume with mobile phase
and sonicated for about 15 min and filtered through 0.45µm membrane filter. From this 5ml was
pipetted out in to a 25ml volumetric flask and made up to the volume with mobile phase.Furthur
diluted to obtain final concentration of  80 µg/ mLof Clidinium bromide and Chlordiazepoxide
respectivelyWith optimized Chromatographic condition a steady base line was recorded with
mobile  phase  10  µl  quantity  of  sample  solution  was  injected  and  the  Chromatogram  was
recorded. The results was tabulated in Table 7 & the chromatogram is shown in Figure 8.
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Procedure:
Inject 10 l of the standard, sample into the chromatographic system and measure the areas
for theClidinium bromide and Chlordiazepoxide.
Amount of drug in tablet was calculated using following formula
Amount present:
                            Sample area X standard weight 
                                                                                 X dilution factor   X average weight
                            Standard area X sample weight
Percentage purity:
                            Amount present / label claim X 100
6.3 METHOD VALIDATION
The chromatographic conditions were validated by evaluating linearity, accuracy, method
precision, limit of detection (LOD), limit of quantitation (LOQ), ruggedness and robustness in
accordance with ICH guidelines.
6.3.1 SPECIFICITY:
 Specificity is the ability to measure accurately and specifically the analyte of interest in the
presence of other components that may be expected to be present in the sample matrix. It is a
measure of the degree of interference from such things as other active ingredients, excipients,
impurities, and degradation products, ensuring that a peak response is due to only to a single
component;  that  is,  that  no  co-elution  exists.  Specificity  is  measured  and  documented  in  a
separation by the resolution, plate count, and tailing factor. 
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Preparation of solutions:
a) Placebo interference:
Sample was prepared by taking the placebo equivalent to about the weight in portion of
test preparation as per the test method and injected into the HPLC system. The chromatogram
was shown in Figure 9.
Acceptance criteria:
Chromatogram of placebo should not show any peak at  the retention time of analyte
peak.
b) Blank Interference 
Mobile  phase  was  prepared  as  per  the  test  method  and  injected  and  into  the  HPLC
system. The chromatogram was shown in Figure 10.
Acceptance criteria:
Chromatogram of blank should not show any peak at the retention time of analyte peak.
6.3.2 SYSTEM SUITABILITY
System Suitability was the checking of a system to ensure system performance before or 
during the analysis of unknowns. Parameters such as plate count, tailing factor, resolution, and 
reproducibility are determined and compared against the specification set for the method. These 
parameters are measured during the analysis of a system suitability sample that is a mixture of 
main components and expected by-product. The results was tabulated in Table-8 & the 
chromatogram was shown in Fig no 13.
6.3.3 LINEARITY:
Preparation of stock solution:
        The quantity containing 5mg of Clidinium bromide and 10mg of Chlordiazepoxide was
weighed and transferred in to a 25ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45µm membrane from this 5ml was
pipetted out in to a 25ml volumetric flask and made up to the volume with the mobile phase. The
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solution  contains  200  µg/  mL and  400  µg/  mL concentration  of  Clidinium  bromide  and
Chlordiazepoxide respectively.
Preparation of linearity solution (50%):
         2.5 mL of stock solution was taken in 25 mL of volumetric flask dilute up to the mark with
diluent. The solution contains 20 µg/ mL and 40 µg/ mL concentration ofClidinium bromide and
Chlordiazepoxiderespectively.
Preparation of linearity solution (75%):
3.75 mL of stock solution was taken in 25 mL of volumetric flask dilute up to the mark with
diluent. The solution contains 30 µg/ mL and 60 µg/ mL concentration ofClidinium bromide and
Chlordiazepoxiderespectively.
Preparation of linearity solution (100%):
5.0 mL of stock solution was taken in 25 mL of volumetric flask dilute up to the mark with
diluent. The solution contains 40 µg/ mL and 80 µg/ mL concentration ofClidinium bromide and
Chlordiazepoxiderespectively.
Preparation of linearity solution (125%):
6.25 mL of stock solution was taken in 25 mL of volumetric flask dilute up to the mark with
diluent.  The solution contains 50 µg/ mL and 100 µg/ mL concentration ofClidinium bromide
and Chlordiazepoxiderespectively.
Preparation of linearity solution (150%):
7.5 mL of stock solution was taken in 25 mL of volumetric flask dilute up to the mark with
diluent.  The solution contains 60 µg/ mL and 120 µg/ mL concentration ofClidinium bromide
and Chlordiazepoxiderespectively.
Procedure:
Each level of the above solutions was injected into the chromatographic system for five
replicate and the peak area was measured. A graph was plotted (peak area versus concentration)
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and the correlation coefficient (r2) was calculated. The results were tabulated in  Table 9& the
chromatograms were shown in Figure 15-21.
6.3.4 PRECISION:
Precision was the measure of the degree of repeatability of an analytical method under normal
operation and it  was normally expressed as  the relative standard deviation for  a statistically
number  of  samples.  Precision  should  be  performed  at  three  different  levels:  repeatability,
intermediate precision and reproducibility.
Standard Preparation:
             The quantity containing 5 mg of Clidinium bromide and 10 mg of Chlordiazepoxide was
weighed and transferred in to a 25 ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this 5
ml was pipetted out in to a 25 ml volumetric flask and made up to the volume with mobile phase.
The  solution  contains  40  µg/  mL and  80  µg/  mL concentration  of  Clidinium bromide  and
Chlordiazepoxide respectively. The chromatogram was shown in Figure 4.
Sample Preparation:
Weigh and powder 20 tablets and weigh powder equivalent  to 444.8 mg of  the sample
was taken and transferred in to a 25ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this
5ml was pipetted out in to a 25ml volumetric flask and made up to the volume with mobile
phase. About 10µl of the sample was injected separately through auto injector the results and the
chromatogram shown in Figure no 22-27. And Table no 10.
Procedure:
         Six replicate Sample solutions were prepared as per the test method and injected as per the 
test procedure
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6.3.5 ACCURACY:
The accuracy of the test method was carried out by preparing the samples at a level of
50%, 100% and 150% of target concentration. The samples were prepared in six times for lower
and higher concentration levels and triplicate the other level and perform the assay as per test
Preparation of Stock Solution:
           The quantity containing 5mg of Clidinium bromide and 10 mg of Chlordiazepoxide was
weighed and transferred in to a 25ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane from this 5ml was
pipetted out in to a 25ml volumetric flask and made up to the volume with the mobile phase.
50% Sample preparation:
         From  the  above  stock  solution1.25  mL containing  of  Clidinium  bromide  and
Chlordiazepoxidewas  taken  into  a  25  mL volumetric  flask  and  diluted  up  to  the mark  with
diluent. The solution was sonicated for 15 min and filtered through 0.45 µm nylon membrane
filter. The above solution were inject into the HPLC column same procedure was repeated for
three replicate.  The results  are tabulated  inTable11-12  & the  chromatograms were  shown in
Figure 28-36.
100% Sample preparation:
         From  the  above  stock  solution2.5  mL  containing  of  Clidinium  bromide  and
Chlordiazepoxidewas  taken  into  a  25  mL volumetric  flask  and  diluted  up  to  the mark  with
diluent. The solution was sonicated for 15 min and filtered through 0.45 µm nylon membrane
filter. The above solution were inject into the HPLC column same procedure was repeated for
three replicate. The results are tabulated in  Table 11-12  & the chromatograms were shown in
Figure 28-36.
150% Sample preparation:
        From  the  above  stock  solution3.75  mL  containing  of  Clidinium  bromide  and
Chlordiazepoxidewas  taken  into  a  25  mL volumetric  flask  and  diluted  up  to  the mark  with
diluent. The solution was sonicated for 15 min and filtered through 0.45 µm nylon membrane
filter. The above solution were inject into the HPLC column same procedure was repeated for
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three replicate.  The results are tabulated in  Table 11-12& the chromatograms were shown in
Figure 28-36.
Procedure: 
  The standard solution was injected in triplicate for Accuracy -50%, Accuracy -100% and
Accuracy -150% solutions. 
         Calculate  the  Amount  found  and  Amount  added  for  Clidinium  bromide  and
Chlordizepoxideand calculate the individual recovery and mean recovery values.
                                     Sample peak area x weight of standard   
         % Recovery   =                                                                   X 100
                                      Standard peak area x weight of sample
6.3.6 RUGGEDNESS (INTERMEDIATE PRECISION):
           Method ruggedness  is defined  as the  reproducibility  of  results  when  the  method  is
performed under  actual  use  conditions.  Theincludesdifferent  analysts,  laboratories, columns,
and instruments,  source  of  reagents,  chemicals,  and  solvents.In the present study, ruggedness
was performed with different analysts. 
Standard Preparation:
             The quantity containing 5 mg of Clidinium bromide and 10 mg of Chlordiazepoxide was
weighed and transferred in to a 25 ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this 5
ml was pipetted out in to a 25 ml volumetric flask and made up to the volume with mobile phase.
The  solution  contains  40  µg/  mL and  80  µg/  mL concentration  of  Clidinium bromide  and
Chlordiazepoxide respectively. The chromatogram was shown in Figure 4.
Sample Preparation:
Weigh and powder 20 tablets and weigh powder equivalent  to 444.8 mg of  the sample
was taken and transferred in to a 25ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this
5ml was pipetted out in to a 25ml volumetric flask and made up to the volume with mobile
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phase. About 10µl of the sample was injected separately through auto injector the results and the
chromatogram shown in Figure no 13-14. And Table no 37-48.
6.3.7 ROBUSTNESS:
The  robustness  of  an  analytical  procedure  is  a  measure  of  its  capacity  to  remain
unaffected  by  a  small,  but  deliberate  variation  in  the  method  parameters  and  provides  an
indication of  its  reliability during normal  usage.  Robustness  of  the method was investigated
under a variety of conditions including deliberate changes in the mobile phase ratio and change
in flow rate. The degree of reproducibility of the results obtained as a result of small variations in
the method parameters has proven that the method is robust.
Standard Preparation:
             The quantity containing 5 mg of Clidinium bromide and 10 mg of Chlordiazepoxide was
weighed and transferred in to a 25 ml volumetric flask and made up to the volume with mobile
phase and sonicated for about 15 min and filtered through 0.45 µm membrane filter. From this 5
ml was pipetted out in to a 25 ml volumetric flask and made up to the volume with mobile phase.
The  solution  contains  40  µg/  mL and  80  µg/  mL concentration  of  Clidinium bromide  and
Chlordiazepoxide respectively. The chromatogram was shown in Figure 49-52 &table 15-16
6.3.8 LIMIT OF DETECTION:
The limit of detection (LOD) is the lowest amount of analyte in a sample that can be
detected but not necessarily quantities under the stated experimental conditions. The detection is
usually expressed as the concentration of the analyte in sample, for example, percentage, parts
per million (ppm), or parts per billion (ppb).
The  LOD  value determined during  method  validation  isaffected  by  the  separa t i on
condit ions  like  columns,  reagents  and  special  instrumentation  and  data  Systems.
Instrumental changes, particularly pumping systems and detectors or the use of contaminated
reagents can result in large changes in result. 
The standarddeviation of  the  Y-intercept  and the  slope  of  the  calibration  curves were
used to calculate the LOD. The chromatogram was shown in fig 62.
LOD= 3.3 * σ / slope
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6.3.9 LIMIT OF QUANTIFICATION:
The Limit of Quantification (LOQ) is a characteristic of quantitative assays for low levels
of compounds in sample matrices, such as impurities in bulk drug substances and Degradation
products in finished pharmaceuticals. The detection is usually expressed as the concentration of
the analyte in the sample, for example, percentage, parts per million (ppm), or parts per billion
(ppb).
The  LOQ  value determined  during  method  validation  is  affected  by  the  separation
conditions:  columns,  reagents  and  special  instrumentation  and  data  Systems.  Instrumental
changes, particularly pumping systems and detectors or the use of contaminated reagents can
result in large changes in result.
The standarddeviation of  the  Y-intercept  and  the  slope  of  the  calibration  curves were
used  to  calculate  the  LOD  by  using  the  equations  10*std.dev/slope  for  LOQ.  The
chromatogram was shown in fig 63.
LOD= 10 * σ / slope
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7. RESULTS AND DISCUSSION
7.1 METHOD DEVELOPMENT:
7.1.1 Isobestic point of Clidinium bromide and Chlordiazepoxide by UV-Visible
spectrophotometry
Fig. 1: Isobestic pointClidinium bromideandChlordiazepoxide 240 nm
Observation:
The overlaid spectrum of  Clidinium bromide of  andChlordiazepoxide shows maximum
absorbance at 240 nmand was used for method development.
7.1.2 DEVELOPMENT TRAILS:
Selection of flow rate:
The flow rate was changed from 1.0-1.5 mL min-1 and the chromatogram was developed.
The drugs eluted with small differences in fronting and tailing except at 1.5 mL min-1 and it was
selected for analysis.
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Trial-1
Table 1: Chromatographic condition 
Parameters Description
Column OC C8 (250 mm x 4.5 mm, 5 µm) 
Mobile Phase Buffer pH 4.0 : Methanol(60:40)
Diluent Water : Methanol(60:40)
Flow rate 1.0 mL min-1
Wavelength 240 nm
Injection mode Auto injector (vial)
Injection volume 10 µL
AU
0.00
0.20
0.40
0.60
Minutes
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00 9.00 10.00
Fig. 2: Chromatogram of Clidinium bromideand Chlordiazepoxide
Observation
Two  peaks  were  merged  with  the  same  retension  time.Clidinium  bromide  and
Chlordiazepoxidewere not eluted properly. So the mobile phase has been changed for next trial.
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Trail 2
Table 2: Chromatographic condition 
Parameters Description
Column OC C8 (250 mm x 4.5 mm, 5 µm) 
Mobile Phase Buffer pH 4.0 : Methanol(70:30)
Diluent Water : Methanol (70:30)
Flow rate 1.2 mL min-1
Wavelength 240 nm
Injection mode Auto injector (vial)
Injection volume 10 µL
Fig.
3:
Observation
Cleft peak was obtained both Clidinium bromide and Chlordiazepoxidewere not eluted
properly. So flow rate has been changed for next trial.
Trail 3
Department of pharmaceutical analysis Page 51
AU
0.00
0.20
0.40
0.60
Minutes
0.00 5.00 10.00 15.00 20.00 25.00 30.00
Chapter 7                Results and Discussion
Table 3: Chromatographic condition 
Parameters Description
Column OC C8 (250 mm x 4.5 mm, 5 µm) 
Mobile Phase Buffer pH 4.0 : Methanol(70:30)
Diluent Water : Methanol (70:30)
Flow rate 1.5 mL min-1
Wavelength 240 nm
Injection mode Auto injector (vial)
Injection volume 10 µL
2.
63
5
AU
0.00
0.20
0.40
0.60
0.80
Minutes
0.00 2.00 4.00 6.00 8.00 10.00 12.00 14.00 16.00 18.00 20.00
Fig. 4: Chromatogram of Clidinium bromideand Chlordiazepoxide
Observation
Single peak was obtained for both components. Henceanother trail was carried out by
changing the mobile phase ratio.
 Trail 4
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Table 4: Chromatographic condition 
Parameters Description
Column OC C8 (250 mm x 4.5 mm, 5 µm) 
Mobile Phase Buffer pH 4.0 : Methanol(80:20)
Diluent Water : Methanol (80:20)
Flow rate 1.5 mL min-1
Wavelength 240 nm
Injection mode Auto injector (vial)
Injection volume 10 µL
2.
62
1
5.
17
2
AU
0.00
0.20
0.40
0.60
0.80
Minutes
0.00 1.00 2.00 3.00 4.00 5.00 6.00 7.00 8.00
Fig. 5: Chromatogram of Clidinium bromideand Chlordiazepoxide
Observation
Clidinium bromide and Chlordiazepoxidepeaks were obtained but Retention time is very
high  and  second  peak  was  not  obtained  properly  next  performed  optimization  method  by
changing the flow rate and pH.
OPTIMIZED METHOD 
Table 5: Chromatographic condition
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Parameters Description
Column OC C8 (250 mm x 4.5 mm, 5 µm) 
Mobile Phase Buffer pH 4.5 : Methanol(80:20)
Diluent Water : Methanol (80:20)
Flow rate 1.5 mL min-1
Wavelength 240 nm
Injection mode Auto injector (vial)
Injection volume 10 µL
Fig. 6: Chromatogram of Clidinium bromideand Chlordiazepoxide
Observation:
Resolution, theoretical plates and symmetric factor were found to be within the limit. So this 
method is finalized as the optimized method.  
ASSAY:
Table 6: Assay data for standard Clidinium bromide and Chlordiazepoxide
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Table 7: Assay data for tablets of Clidinium bromide and Chlordiazepoxide
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S.No
Standard
Clidinium bromide Chlordiazepoxide
1 374688 753761
2 375210 753617
3 374921 753711
Mean 374939 753696
S.No
Standard
Clidinium bromide Chlordiazepoxide
1 387781 751750
2 387688 751617
3 387921 751711
Avg 387796 751692
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Fig. 7:Standard chromatogram of Clidinium bromide and Chlordiazepoxide
Fig.no.8
Fig. 8:Chromatogram of marketed formulation ofClidinium bromide and Chlordiazepoxide
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Formula:
Amount present:    Sample area X standard weight
                                                                                    X dilution factor X average weight
                                Standard area X sample weight 
Percentage purity: Amount present/label claim X 100
For Clidinium bromide:
=  387796×5×5×25×25×99.8×222.4×100
    374939×25×25×444.8×5×100×2.5
 = 1.0026×99.8
 = 100.05%                                                   
ForChlordiazepoxide:
=751692×10×5×25×25×99.8×222.4×100
   753696×25×25×444.8×5×100×5
= 1.0039×99.8
= 100.1%
7.2 METHOD VALIDATION
7.2.1 SPECIFICITY:
Specificity  is  the  ability  to  assess  unequivalently  the  analyte  in  the  presence  of
components,  which may be expected to be present.  Typically these might include impurities,
matrix, degradants etc.  It  is evaluated by injecting the blank and the control sample solution
prepared as per the proposed method to check for the interference if any peak at the retention
time of Clidinium bromide and Chlordiazepoxide.
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The specificity of the HPLC method was complete separation of Atazanavirsulphate and
Ritonavir was noticed in presence of tablet excipients. In addition there was no interference at
the retention time of  Clidinium bromide  and Chlordiazepoxidein the chromatogram of placebo
solution.
Name of the solution Retention time in min
Blank No peak
Placebo No peak
Standard 3.57 and 5.39
Sample 3.57 and 5.40
Fig. 9: Chromatogram of placebo solution
Fig. 10: Chromatogram of blank solution
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Fig. 11: Chromatogram of standard formulation of Clidinium bromide and Chlordiazepoxide
Fig. 12: Chromatogram of marketed formulation of Clidinium bromide and Chlordiazepoxide
Result:
The method was found to be specific because it did not show any extra peaks and there is
no interference from excipients. 
7.2.2 SYSTEM SUITABILITY
Suitability is a measure of the precision under the same operating conditions over a short
interval of time, that is, under normal operating conditions of the analytical method with the
same equipment. The chromatograms obtained for suitability were shown in fig no 13. and the
parameters were shown in table no 8.
Table 8: System Suitability Parameters
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S. No Parameters Clidiniumbromide
Chlordiazepoxid
e
1 Theoretical plates 4688 5761
2 RT 3.578 5.39
3 Resolution 12.36 12.68
4 Tailing factor 1.129 1.072
Fig. 13: Chromatogram of standard formulation of Clidinium bromide and Chlordiazepoxide
Acceptance criteria:
Theoretical plate’s ≥ 2000, symmetric factor ≤ 2, tailing factor ≤ 2.
Result:
From the above table it was concluded that result obtained was within the limit only.
7.2.3 LINEARITY:
The linearity  of  calibration  curves  (Absorbance  Vs concentration)  in pure  solution
was checkedover the concentration ranges of about 60-180µg/ml for Clidinium bromide and
chlordiazepoxide. The results were tabulated in table no 9and figure no 15-21.
Table 9:  Linearity of Clidinium bromide and Chlordiazepoxide
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S.No. Clidinium bromide
Chlordiazepoxide
Conc. (µg mL-1) Peak Area Conc. (µg mL-1) Peak Area
1 20 190127 40 366951
2 30 285491 60 550758
3 40 380605 80 733006
4 50 476653 100 917184
5 60 571015 120 1105711
Slope 3174.6 6132.9
Y-Intercept 141.9 1020.1
Correlation
coefficient
0.999 0.999
0 20 40 60 80 100 120 140 160 180 200
0
200000
400000
600000
800000
1000000
1200000
f(x) = 6132.88x - 1020.14
R² = 1
Concentration
A
re
a
Fig. 15: Calibration plot of Clidinium bromide
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Fig. 16: Calibration plot of Chlordiazepoxide
Fig. 17: Chromatogram of Clidinium bromide and Chlordizepoxidefor Linearity-1
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Fig. 18: Chromatogram of Clidinium bromide and Chlordizepoxidefor Linearity-2
Fig. 19: Chromatogram of Clidinium bromide and Chlordizepoxidefor Linearity-3
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Fig. 20: Chromatogram of Clidinium bromide and Chlordizepoxidefor Linearity-4
Fig. 21: Chromatogram of Clidinium bromide and Chlordizepoxidefor Linearity-5
Acceptance criteria: 
Correlation Coefficient should be not less than 0.9990
Department of pharmaceutical analysis Page 64
Chapter 7                Results and Discussion
Result:
              The relationship between the concentration and the peak response of Clidinium bromide
and Chlordiazepoxide was linear in the specific range and the regression coefficient was found to
be 0.999 for bothClidinium bromide and Chlordiazepoxide
7.2.4 PRECISION:
Precision is a measure of the reproducibility of the whole analytical method under
normal  operating circumstances.  Precision is  determined by using the method to assay a
sample for a sufficient number of times to obtain statistically valid results. The precision is
then expressed in terms of relative standard deviation. Acceptance criteria for the precision of
the method is  the %RSD should not be more than 2%.The results for the precision were
shown in following table no 10.And figure no 22-27.
Table 10 Method Precision:
S.no
Clidinium bromide Chlordiazepoxide
Peak area RT Peak area RT
1 380537 3.581 733626 5.414
2 380607 3.585 733307 5.418
3 380412 3.584
733012 5.419
4 380102 3.583 733006 5.419
5 380742 3.583 733903 5.422
6 380766 3.583 733977 5.423
Mean 380527.6 733471
SD 60739 191.88
RSD % 0.06 0.02
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Fig. 22: Chromatogram of Clidinium bromide and Chlordizepoxidefor Precision-1
Fig. 23: Chromatogram of Clidinium bromide and Chlordizepoxidefor Precision-2
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Fig. 24: Chromatogram of Clidinium bromide and Chlordizepoxidefor Precision-3
Fig. 25: Chromatogram of Clidinium bromide and Chlordizepoxidefor Precision-4
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Fig. 26: Chromatogram of Clidinium bromide and Chlordizepoxidefor Precision-5
Fig. 27: Chromatogram of Clidinium bromide and Chlordizepoxidefor Precision-6
Acceptance Criteria: 
% RSD of the sample replicate should not be more than 2. 
Result
The  %  RSD  for  Clidinium  bromide  and  chlordiazepoxidewas  found  to  be  0.06  and  0.02
respectively. The % RSD value indicates a good degree of precision within the specified range.
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7.2.5 ACCURACY
Accuracy of  the method  was  determined  by recovery  experiments. To the
formulation,  the  reference  standards  of  the drug were  added  at  the  level  of 50%, 100%,
150%. The recovery studies were carried out  three  times and the percentage recovery and
percentage  relative  standard  deviation  of  the  recovery  werecalculated  and  shown  in
table no 11-12. And figure no 28-36.
Table11:Accuracy for Clidinium Bromide
AMOUNT
OF
SPIKED
Peak Area
Amount
of added
(mg)
Amount
recovered
(mg)
%
Recover
y
Average
recovery
%
RSD
50%
190405 1.25 1.24 100.80
100.53 0.45190497
1.25
1.24 100.80
190659
1.24
1.24 100.00
100%
380225
2.5
2.48 100.80
100.40 0.39380833
2.47
2.46 100.40
380206
      2.5
2.5 100.00
150%
571440 3.75 3.74 100.26
100.53 0.26
571664 3.73 3.71 100.53
571077 3.74 3.71 100.80
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Table 12: Accuracy for Chlordiazepoxide
AMOUNT
OF
SPIKED
Peak
Area
Amount of
added
(mg)
Amount
recovered
(mg)
%
Recover
y
Average
recovery
%
RSD
50%
366024 2.50 2.49 100.40
100.67 0.23
366893
2.48
2.46 100.81
366878
2.49
2.47 100.80
100%
733451 5.0 4.97 100.60
100.40 0.19733244
4.98
4.96 100.40
733399 4.99 4.98 100.20
150%
1108041
7.5
7.49 100.13
100.26 0.131106428
7.48
7.45 100.40
1109336 7.49 7.47 100.26
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Fig. 28: Chromatogram of Clidinium bromide and Chlordiazepoxidefor 50%spiking-1
Fig. 29: Chromatogram of Clidinium bromide and Chlordiazepoxidefor 50%spiking-2
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Fig. 30: Chromatogram of Clidinium bromide and Chlordiazepoxidefor 50%spiking-3
Fig. 31: Chromatogram of Clidinium bromide and Chlordiazepoxidefor 100%spiking-1
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Fig. 32: Chromatogram of Clidinium bromide and Chlordiazepoxidefor 100%spiking-2
Fig. 33: Chromatogram of Clidinium bromide and Chlordiazepoxidefor 100%spiking-3
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Fig. 34: Chromatogram of Clidinium bromide and Chlordiazepoxidefor 150%spiking-1
Fig. 35: Chromatogram of Clidinium bromide and Chlordiazepoxidefor 150%spiking-2
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Fi
g. 36: Chromatogram of Clidinium bromide and Chlordiazepoxidefor 150%spiking-3
Acceptance criteria:
           The mean percentage recovery of the Clidinium bromide and Chlordiazepoxideat each
spike level should be not less than 98.0% and not more than 102.0%.
Result
From the Accuracy table it was found that % Recovery of the drug was found to be in the
range of 100.40-100.53 % and 100.26-100.67 % for Clidinium bromide and Chlordiazepoxide
respectively. This indicates that the method was accurate. 
7.2.6 RUGGEDNESS 
Ruggedness is the degree of reproducibility of results obtained by the analysis of the
same sample under a  variety of normal test conditions i.e.  different  analysts.  Acceptance
criteria for ruggedness,the %RSD should not be more than 2%. Results of this study were
shown in table no 13-14 and figure no 37-48.
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Table13:Intraday Precision and Intermediate precision Analyst - 1
Parameter Inj
Clidiniumbromide Chlordiazepoxide
Rt AUC %ASSAY Rt AUC %ASSAY
Intraday
Precision
Data
Analyst-1
1 3.593 571440 99.78 5.447 1108041 100.42
2 3.592 571664 99.14 5.448 1106428 100.26
3 3.592 571077 99.56 5.450 1109336 100.00
4 3.594 571988 99.60 5.450 1109177 100.32
5 3.594 571855 99.41 5.445 1100070 100.65
6 3.594 571184 99.80 5.444 1105351 98.94
Mean 571534 99.55 1106401 100.10
R.S.
D
0.06 0.31
Table14: Intraday Precision and Intermediate precision Analyst - 2
Parameter Inj
Clidiniumbromide Chlordiazepoxide
Rt AUC %ASSAY Rt AUC %ASSAY
Intraday
Precision
Data
Analyst-2
1 3.553 571540 100.05 5.407 1112045 100.12
2 3.572 571464 99.21 5.418 1113421 99.60
3 3.552 571177 99.88 5.410 1112332 101.49
4 3.564 571688 100.15 5.400 1114179 100.89
5 3.574 571555 98.86 5.385 1110073 100.38
6 3.584 571284 99.78 5.374 1112355 100.44
Mean 571451 99.65 1112401 100.49
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%R.S.
D
0.03 0.12
Fig. 37: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -1
Fig. 38: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -2
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Fig. 39: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -3
Fig. 40: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -4
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Fig. 41: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -5
Fig. 42: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -6
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Fig. 43: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -1
Fig. 44: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -2
Department of pharmaceutical analysis Page 80
Chapter 7                Results and Discussion
Fig. 45: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -3
Fig. 46: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -4
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Fig. 47: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -5
Fig. 48: Chromatogram of Clidinium bromide and Chlordiazepoxidefor ruggedness -6
Acceptance criteria:
%RSD not more than 2%
Result:
Individual % RSD of Assay was found to be 0.25 % and 0.60 %.  The Relative standard
deviation  of  %  Assay  of  Analyst  1  found  to  be  for  Clidinium  bromide  0.06  %  and
Chlordiazepoxide 0.31 % and the sample passed the test. The relative standard deviation of %
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Assay of Analyst 2 found to be for Clidinium bromide 0.03 % and Chlordiazepoxide0.12 %
respectively.
7.2.7 ROBUSTNESS:
The robustness study was carried out for variation flow rate and temperature 
The of variation flow rates was shown in table no15-16andresults are shown in figure no49-52.
Table no.15: Flow rate changes for Clidinium bromide and Chlordiazepoxide
Clidinium bromide Chlordiazepoxide
Flow
rate
Retention
time
Peak
area
Plate count Retention
time
Peak
area
Plate count
1.2 4.465 483250 9055 6.789 936068 9245
1.8 2.988 325035 7093 4.536 622136 7245
Fig. 49: Flow rate changes (Flow rate 1.2mL)
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Fig. 50: Flow rate changes (Flow rate 1.8mL)
Table: 16: Temperature changes for Clidinium bromide and Chlordiazepoxide
Clidinium bromide Chlordiazepoxide
Tempe
rature
(oC)
Retention
time
Peak
area
Plate
count
Retention
time
Peak
area
Plate count
28 3.582 385490 8034 5.438 752227 8150
30 3.563 395511 8921 5.644 750899 8454
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Fig. 51: Temperature changes (Temperature 280c)
Fig. 52: Temperature changes (Temperature 300c)
Result:
When flow rate  was altered  RT has  no changed  significantly,  when temperature was
altered there was no change in the RT significantly. The method was found to be robust as per
ICH Guidelines.
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7.2.8 LIMIT OF DETECTION (LOD) AND LIMIT OF QUANTITATION (LOQ):
LOD and LOQ were calculated by using instrumental method. 
Limit of detection:
Detection limit were calculated by the method based on the standard deviation ( ) and slope of 
the calibration plot, using the formula
Limit of Detection σ                        =  × 3.3
                                                                    S
                            σ = Standard deviation
                            S = Slope of the calibration curve
Limit of quantification:
Detection limit were calculated by the method based on the standard deviation ( σ) and
slope of the calibration plot, using the formula
          Limit of Quantitation  σ         = × 10
S
                σ = Standard deviation
                            S = Slope of the calibration curve
Table 17: LOD and LOQ
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Sample LOD LOQ
Clidinium bromide 0.49 µg/ml 1.6 µg/ml
Chlordiazepoxide 0.8 µg/ml 2.8 µg/ml
Chapter 7                Results and Discussion
Fig. 61:
LOD
Fig. 62:  LOQ chromatogram of Clidinium bromide and Chlordiazepoxide
Acceptance criteria:
LOD should not exceed LOQ.
Result:
TheLOD and LOQ of Clidinium bromide is 0.49 and 1.6
The LOD and LOQ of Chlordiazepoxide is 0.8 and 2.8.
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8. SUMMARY AND CONCLUSION
In the present study, new RP-HPLC method for simultaneous estimation of  Clidinium
bromide and Chlordiazepoxide in bulk and pharmaceutical dosage form was developed.  The
developed  method  was  validation  for  various  parameters  such  as  accuracy,  precision,
ruggedness, linearity,  robustness, system suitability, specificity, limit of detection and limit of
quantification as per ICH guidelines.
The results of the studies are summarized as follows
A) Method development:
 Trial  5  was  optimized  for  the  method  development  of  deliberately  changing  the
chromatographic conditions.
 Column used was OC C8 (250 x 4.5mm, 5.0µm), mobile phase composition of Buffer pH
4.5 : Methanol (80:20), Flow rate 1.5 mL min-1.UV detection was carried out at 240 nm.
 Assay  percentage  was  found  to  be  100.05  %  for  Clidinium  bromide  and  100.1  %
forChlordiazepoxide.
B) Validation Parameters:
 The calibration was linear with correlation coefficient  0.999 for Clidinium bromide and
0.999 forChlordiazepoxide.
 In precision it was found that % RSD is less than 2% which indicates that the 
proposed method has good reproducibility.
 The system suitability parameter indicates good resolution of both the peaks > 2.
 From the Accuracy was found that % Recovery of the drug was found to be in the range
of 100.40-100.53% and 100.26-100.67% for Clidinium bromide  and  Chlordiazepoxide
respectively.
 Robustness,  When  flow  rate  was  altered  RT  has  no  changed  significantly,  when
temperature was altered there was no change in the RT significantly.
 LOD and LOQ, the limit of detection (LOD) was 0.49 µg mL-1 for Clidinium bromide
and 0.8 µg mL-1 for Chlordiazepoxide and the limit of quantitation (LOQ) was 1.6 µg
mL-1  for Clidinium bromide and 2.8 µg mL-1  for Chlordiazepoxide.
Conclusion
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The developed RP-HPLC method has been successfully applied for the simultaneous
determination  of  Clidinium  bromide  and  Chlordiazepoxide in  pure  drug  and  marketed
formulation. The methods are found to be rapid, simple, accurate and convenient to adopt. The
developed methods are completely validated with all validation parameters.The results indicate
that this method are precise, accurate further more it is easy and convenient for routine drug
analysis.
Plan for further study
The proposed method was simple, precise and accurate. Furthermore methods can be
developed by the sophisticated instruments like GC-MS and LC-MS and stability studies can
be carried by using RP-HPLC.
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10. APPENDIX
% : Percentage
µ mol             :                       Micromole
µg : Microgram
14C : Carbon - 14
3H :  Tritium
ACN : Acetonitrile
API : Active Pharmaceutical Ingredient
AUC : Area under Curve
CAS : Chemical Abstracts Service
cm : Centimetre
EGFR :  Epidermal Growth Factor 
FDA : Food and Drug Administration
Fig                          :  Figure
GC : Gas chromatography
HETP : High equivalent theoretical plate
HPLC :  High-performance liquid 
HPTLC :  High-performance thin layer 
K :  Tailing Factor
LC : Liquid chromatography
LC-MS                        :  Liquid chromatography-Mass 
LOD :  Limit of detection
LOQ : Limit of quantification
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mg : Milligram
Min : Minute
mm : Millimeter
MS : Mass Spectroscopy
NF : National Formulary
nm :  Nanometer
NSCLC             :  Non - small Cell Lung Cancer
ODS : Octyldecylsilane
RI :  Refractive Index
RI : Refractive index
RP-HPLC             : Reversed-phase high-performance liquid 
Rs : Resolution
RSD : Relative standard deviation
S : Separation from Peak
S/N : Signal to Noise ratio
SD : Standard Deviation
TLC : Thin layer chromatography
USFDA : United States Food and Drug Administration
USP : United States Pharmacopoeia
UV : Ultraviolet
v/v : Volume by volume
WHO : World Health Organization
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